All study treatments administered BID.

Top- BEVESPI AEROSPHERE is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
- In Trial 1, the mean increase in FEV
_{1}at 5 minutes after the first dose vs placebo (n=172) was 187 mL for BEVESPI AEROSPHERE (n=418), 44 mL for glycopyrrolate 18 mcg (n=363), and 184 mL for formoterol fumarate 9.6 mcg (n=366). The mean increase in FEV_{1}at 120 minutes after the first dose vs placebo (n=218) was 260 mL for BEVESPI AEROSPHERE (n=523), 136 mL for glycopyrrolate 18 mcg (n=448), and 229 mL for formoterol fumarate 9.6 mcg (n=441) (*P*<0.0001 for all)^{1-3} - Statistically significant improvement was also demonstrated in Trial 2 with the mean increase in FEV
_{1}at 5 minutes after the first dose vs placebo (n=179) of 186 mL for BEVESPI AEROSPHERE (n=429), 46 mL for glycopyrrolate 18 mcg (n=371), and 169 mL for formoterol fumarate 9.6 mcg (n=375). The mean increase in FEV_{1}at 120 minutes after the first dose vs placebo (n=221) was 267 mL for BEVESPI AEROSPHERE (n=506), 127 mL for glycopyrrolate 18 mcg (n=435), and 227 mL for formoterol fumarate 9.6 mcg (n=433) (*P*<0.0001 for all)^{1,2,4} - Adverse reactions with BEVESPI AEROSPHERE with a ≥2% incidence and more common than placebo were urinary tract infection and cough
^{1}

**References:
**
**1.
** BEVESPI AEROSPHERE [Package Insert]. Wilmington, DE: AstraZeneca; 2016.
**2.
** Martinez FJ et al. *Chest*. 2017;151(2):340-357.
**3.
** Data on File, 3236300, AZPLP.
**4.
** Data on File, 3236400, AZPLP.